Literature DB >> 3485649

Serum bone Gla protein: a marker of bone turnover in hyperthyroidism.

D R Garrel, P D Delmas, L Malaval, J Tourniaire.   

Abstract

Serum bone Gla protein (BGP) concentrations were measured in 24 hyperthyroid patients before and after treatment. Before treatment, the mean concentration was higher [11.8 +/- 3.4 ( +/- SD) ng/ml] in the patient group than in a group of 12 age-matched normal subjects (6.1 +/- 1.7 ng/ml; P less than 0.001); 16 of the 24 patients had a value above the normal range. Serum BGP concentrations in the patients correlated significantly with serum T3 (r = 0.65; P less than 0.001) and T4 concentrations (r = 0.56; P less than 0.01). Other biochemical markers of bone metabolism (serum alkaline phosphatase, serum and urinary calcium, and urinary hydroxyproline) did not correlate with circulating thyroid hormone levels. Serum BGP also was measured after the patients had become euthyroid; 23 measurements were made on 16 patients at various times after the start of treatment. All values were normal after 16 weeks; before this period, most of the values were still above the normal range despite normal plasma thyroid hormone concentrations in all patients. These results suggest that BGP is a sensitive marker of bone metabolism alterations during hyperthyroidism.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3485649     DOI: 10.1210/jcem-62-5-1052

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  9 in total

1.  Serum osteocalcin levels in breast cancer patients.

Authors:  P Pietschmann; C Zielinski; W Woloszczuk
Journal:  J Cancer Res Clin Oncol       Date:  1989       Impact factor: 4.553

2.  A longitudinal assessment of bone loss in women with levothyroxine-suppressed benign thyroid disease and thyroid cancer.

Authors:  M T McDermott; J J Perloff; G S Kidd
Journal:  Calcif Tissue Int       Date:  1995-06       Impact factor: 4.333

3.  Serum bone Gla protein as a marker of bone turnover in acromegaly.

Authors:  M Marazuela; B Astigarraga; M J Tabuenca; J Estrada; F Marín; T Lucas
Journal:  Calcif Tissue Int       Date:  1993-06       Impact factor: 4.333

4.  Increased rat femur osteocalcin mRNA concentrations following in vivo administration of thyroid hormone.

Authors:  D S Ross; R Graichen
Journal:  J Endocrinol Invest       Date:  1991-10       Impact factor: 4.256

5.  Serum concentrations of osteocalcin in patients with hyperthyroidism, hypothyroidism and subacute thyroiditis.

Authors:  N Kojima; S Sakata; S Nakamura; K Nagai; H Takuno; T Ogawa; I Matsui; H Sarui; K Miura
Journal:  J Endocrinol Invest       Date:  1992 Jul-Aug       Impact factor: 4.256

6.  Osteocalcin and bone morphometric parameters in adults without bone disease.

Authors:  M Garcia-Carrasco; M Gruson; M C de Vernejoul; M A Denne; L Miravet
Journal:  Calcif Tissue Int       Date:  1988-01       Impact factor: 4.333

7.  Bone mineral metabolism and thyroid replacement therapy in congenital hypothyroid infants and young children.

Authors:  G Weber; S Mora; A Bellini; M Bosco; C Prinster; V Siragusa; B di Natale; G Chiumello
Journal:  J Endocrinol Invest       Date:  1995-04       Impact factor: 4.256

Review 8.  Bone disease in thyrotoxicosis.

Authors:  P Amaresh Reddy; C V Harinarayan; Alok Sachan; V Suresh; G Rajagopal
Journal:  Indian J Med Res       Date:  2012-03       Impact factor: 2.375

9.  Metabolic and clinical consequences of hyperthyroidism on bone density.

Authors:  Jagoda Gorka; Regina M Taylor-Gjevre; Terra Arnason
Journal:  Int J Endocrinol       Date:  2013-07-22       Impact factor: 3.257

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.